Vanda Pharmaceuticals' VQW-765 Fails Phase III Trial for Social Anxiety Disorder

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-15
Category: health
Source: The Clinical Trial Vanguard

Vanda Pharmaceuticals announced that its investigational drug VQW-765 did not meet its primary endpoint in a Phase III clinical trial for the acute treatment of social anxiety disorder. The program is now on hold pending further analysis of the full dataset.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai